Literature DB >> 2261014

Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties.

M Reiffen1, W Eberlein, P Müller, M Psiorz, K Noll, J Heider, C Lillie, W Kobinger, P Luger.   

Abstract

Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic alpha-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or beta-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibitors. The prototype falipamil (2) has been submitted to further optimization mainly by manipulation of the phthalmidine moiety. This has resulted in a second generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepinone ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261014     DOI: 10.1021/jm00167a033

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Antiarrhythmics--from cell to clinic: past, present, and future.

Authors:  J C Hancox; K C Patel; J V Jones
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

2.  EC18 as a Tool To Understand the Role of HCN4 Channels in Mediating Hyperpolarization-Activated Current in Tissues.

Authors:  Maria Novella Romanelli; Martina Del Lungo; Luca Guandalini; Mehrnoush Zobeiri; András Gyökeres; Tamás Árpádffy-Lovas; Istvan Koncz; Laura Sartiani; Gianluca Bartolucci; Silvia Dei; Dina Manetti; Elisabetta Teodori; Thomas Budde; Elisabetta Cerbai
Journal:  ACS Med Chem Lett       Date:  2019-02-06       Impact factor: 4.345

3.  Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2.

Authors:  E Delpón; C Valenzuela; O Pérez; L Franqueza; P Gay; D J Snyders; J Tamargo
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Semi-rigid analogues of the calcium antagonist verapamil: a molecular modelling study.

Authors:  M N Romanelli; S Dei; S Scapecchi; E Teodori; F Gualtieri; R Budriesi; R Mannhold
Journal:  J Comput Aided Mol Des       Date:  1994-04       Impact factor: 3.686

5.  3-(3-Chloro-prop-yl)-7,8-dimeth-oxy-1H-3-benzazepin-2(3H)-one at 125 K.

Authors:  Xiang-Wei Cheng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-04-26

6.  3-(3-Chloro-prop-yl)-7,8-dimeth-oxy-2,3,4,5-tetra-hydro-1H-3-benzazepin-2-one at 125 K.

Authors:  Xiang-Wei Cheng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-04-04

Review 7.  HCN Channels Modulators: The Need for Selectivity.

Authors:  Maria Novella Romanelli; Laura Sartiani; Alessio Masi; Guido Mannaioni; Dina Manetti; Alessandro Mugelli; Elisabetta Cerbai
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  Synthesis of Polyheterocyclic Pyrrolo[3,4-b]pyridin-5-ones via a One-Pot (Ugi-3CR/aza Diels-Alder/N-acylation/aromatization/SN2) Process. A Suitable Alternative towards Novel Aza-Analogues of Falipamil.

Authors:  Angel Zamudio-Medina; Ailyn N García-González; Genesis K Herrera-Carrillo; Daniel Zárate-Zárate; Adriana Benavides-Macías; Joaquín Tamariz; Ilich A Ibarra; Alejandro Islas-Jácome; Eduardo González-Zamora
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.